Fairmount Funds Management LLC
Director, 10% Owner · CRESCENT BIOPHARMA, INC.
Every open-market stock purchase Fairmount Funds Management LLC has reported to the SEC on Form 4 that met our signal bar, parsed straight from the filings. This page tracks where how the prices paid compare to where the stock trades now.
Where the buys stand today
- COGTCogent Biosciences, Inc.
One purchase totalling $25.0M at an average of $9.00 per share. See all insider buying in COGT →
Avg price paid$9.00Latest price—Market capUnknown - VRDN+11.7% vs price paidViridian Therapeutics, Inc.\DE
One purchase totalling $20.0M at an average of $17.00 per share; the stock last traded at $18.99. See all insider buying in VRDN →
Avg price paid$17.00Latest price$18.99Market cap$2.1B - CBIOCRESCENT BIOPHARMA, INC.
One purchase totalling $12.4M at an average of $14.50 per share. See all insider buying in CBIO →
Avg price paid$14.50Latest price—Market capUnknown - ZBIO+40.0% vs price paidZenas BioPharma, Inc.
One purchase totalling $3.0M at an average of $20.00 per share; the stock last traded at $28.00. See all insider buying in ZBIO →
Avg price paid$20.00Latest price$28.00Market cap$1.8B
All reported buys
Follow new qualifying clusters involving Fairmount Funds Management LLC or other insiders
Explore qualifying clusters from public SEC filings. Pro adds email and Telegram notifications after detection.
About this data
Figures are parsed from Fairmount Funds Management LLC's Form 4 filings on SEC EDGAR (CIK 1802528) and cover open-market purchases (transaction code P) — grants, option exercises, and sales are excluded, which is why totals here can differ from raw filing counts. Every row links to its source document.
This page is informational and reflects public filing data. It is not investment advice.